Evidence map›Paper›PMID 34223066›Full record

ReviewJAC-antimicrobial resistance2021

Treatment of methicillin-resistant

Nicholas M Brown, Anna L Goodman, Carolyne Horner, Abi Jenkins, Erwin M Brown

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in JAC-antimicrobial resistance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Article
  9. Article
  10. [Multidrug resistance and new anti-infective agents].Innere Medizin (Heidelberg, Germany) · 2026
    Review
  11. Article
  12. The global epidemiology of MRSA.JAC-antimicrobial resistance · 2026
    Review
  13. Article
  14. CutaneousInternational journal of molecular sciences · 2026
    Review
  15. Article
  16. Article
  17. Treatment of Methicillin-ResistantMedicines (Basel, Switzerland) · 2026
    Review
  18. Article
  19. Article
  20. Article

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nicholas M BrownCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Anna L GoodmanGuy's and St Thomas' NHS Foundation Trust, London, UK.
Carolyne HornerBritish Society for Antimicrobial Chemotherapy, Birmingham, UK.
Abi JenkinsBritish Society for Antimicrobial Chemotherapy, Birmingham, UK.
Erwin M BrownBritish Society for Antimicrobial Chemotherapy, Birmingham, UK.

Funding

Medical Research Council MC_UU_00004/05Medical Research Council MC_UU_12023/22
6 · The paper itself

Abstract

These evidence-based guidelines are an updated version of those issued in 2008. They have been produced following a review of the published literature (2007-18) pertaining to the treatment of infections caused by MRSA. The guidelines update, where appropriate, previous recommendations, taking into account changes in the UK epidemiology of MRSA, ongoing national surveillance data and the efficacy of novel anti-staphylococcal agents licensed for use in the UK. Emerging therapies that have not been licensed for use in the UK at the time of the review have also been assessed.

Identifiers

PMID34223066
PMCPMC8210269

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.